Comparative Pharmacology
Head-to-head clinical analysis: DELTASONE versus EMFLAZA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DELTASONE versus EMFLAZA.
DELTASONE vs EMFLAZA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Prednisone is a prodrug that is converted to prednisolone, which binds to the glucocorticoid receptor, leading to altered gene expression and suppression of inflammatory mediators, immune cells, and cytokine production.
Agonist at glucocorticoid receptors, modulating gene expression to suppress inflammation and immune response.
5-60 mg orally once daily or divided twice daily; dose individualized based on condition and response.
0.6 mg/kg orally once daily (maximum 60 mg/day); titrate to lowest effective dose based on clinical response.
None Documented
None Documented
The terminal elimination half-life of prednisolone (active form) is 2.1–3.5 hours. In clinical context, this short half-life supports once-daily to twice-daily dosing for anti-inflammatory effects, but adrenal suppression can persist longer due to receptor binding.
6.2 hours (range 4.5–8.1 h) in healthy adults; prolonged in hepatic impairment.
Prednisone is a prodrug converted to prednisolone. Prednisolone is metabolized primarily in the liver. Renal excretion of unchanged drug is negligible (<1%). Metabolites are excreted renally (approximately 80% as glucuronides and sulfates) and to a small extent in feces (<5%). Biliary excretion is minimal.
Renal excretion of inactive metabolites; less than 5% excreted as unchanged drug in urine. Biliary/fecal elimination accounts for <1%.
Category C
Category C
Corticosteroid
Corticosteroid